Therapy for Experimental Parkinson using ES cells

Information

  • Research Project
  • 7496966
  • ApplicationId
    7496966
  • Core Project Number
    R01NS057850
  • Full Project Number
    5R01NS057850-03
  • Serial Number
    57850
  • FOA Number
    PAR-05-082
  • Sub Project Id
  • Project Start Date
    8/15/2006 - 18 years ago
  • Project End Date
    5/31/2011 - 13 years ago
  • Program Officer Name
    SUTHERLAND, MARGARET L
  • Budget Start Date
    6/1/2008 - 16 years ago
  • Budget End Date
    5/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    3
  • Suffix
  • Award Notice Date
    5/28/2008 - 16 years ago

Therapy for Experimental Parkinson using ES cells

[unreadable] DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a worldwide degenerative and progressive condition characterized by tremor and rigidity. PD is caused by the loss of dopaminergic neurons in the substancia nigra pars compacta, which innervate the striatum and provide it with dopamine (DA). Embryonic stem (ES) cells are known to replicate and to differentiate to several nerve cells, including DA neurons. In fact, dopaminergic cells generated from mouse ES cells can reverse the behavioral abnormalities present in experimental models of PD. To have experimental models has been very useful to study the therapeutic value of different approaches. In this proposal, we want to know what are the modifications in DA neuron markers induced by grafting ES cell- derived-DA neurons in the striatum or the substantia nigra. We also want to establish if cell therapy with mouse ES cell-derived progeny can reconstitute the natural nigro-striatal pathway by. To answer this, we will graft DA neurons in the substancia nigra at different stages of development, from fetuses to adults. Since it has been shown that adult brains are a poor permissive environment for axonal growth, we will use strategies that could promote regeneration of the lost DA trait. Previous results show that grafting ES cells in the striatum can partially restore DA levels. However, a higher basal DA concentration was found in grafted animals. Therefore, we will conduct microdialysis experiments after grafting parkinsonian rats with mutant ES cells to find out if DA concentration in vivo is regulated by mechanisms of neuronal nature (i.e. DA synaptic release and DA uptake). We want to differentiate ES cells null for synaptic release, and devoid of DA transporter activity to DA neurons, and graft them to study the behavioral recovery provided by these genetically modified mouse ES cells. All these approaches can help us understand the basic Biology of stem cell, differentiation, and test if recovery is achieved, to consider translating them to the clinic in the long term. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R01
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    47191
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    FIC:3884\NINDS:43307\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO
  • Organization Department
  • Organization DUNS
    811616333
  • Organization City
    MEXICO D.F.
  • Organization State
  • Organization Country
    MEXICO
  • Organization Zip Code
    04510
  • Organization District
    MEXICO